Compare Stocks: PBH, AXSM, LNTH, and AMRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$21.03 +3.2%	$18.79	$9.99 ▼ $21.17	$6.71B	1.22	2.34 million shs	1.23 million shs
AXSM Axsome Therapeutics	$143.99 -0.7%	$191.71	$123.50 ▼ $260.19	$7.54B	0.86	762,666 shs	621,903 shs
LNTH Lantheus	$99.93 +0.1%	$100.30	$50.15 ▼ $111.86	$6.53B	-0.06	1.09 million shs	271,346 shs
PBH Prestige Consumer Healthcare	$48.26 +1.0%	$48.81	$42.62 ▼ $71.07	$2.29B	0.34	561,298 shs	414,435 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	0.00%	+6.26%	+3.09%	+12.66%	+93.18%
AXSM Axsome Therapeutics	0.00%	-7.70%	-25.65%	-39.15%	+11.96%
LNTH Lantheus	0.00%	+0.10%	+0.06%	-7.62%	+78.02%
PBH Prestige Consumer Healthcare	0.00%	-4.22%	+2.72%	-5.20%	-23.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$21.03 +3.2%	$18.79	$9.99 ▼ $21.17	$6.71B	1.22	2.34 million shs	1.23 million shs
AXSM Axsome Therapeutics	$143.99 -0.7%	$191.71	$123.50 ▼ $260.19	$7.54B	0.86	762,666 shs	621,903 shs
LNTH Lantheus	$99.93 +0.1%	$100.30	$50.15 ▼ $111.86	$6.53B	-0.06	1.09 million shs	271,346 shs
PBH Prestige Consumer Healthcare	$48.26 +1.0%	$48.81	$42.62 ▼ $71.07	$2.29B	0.34	561,298 shs	414,435 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	0.00%	+6.26%	+3.09%	+12.66%	+93.18%
AXSM Axsome Therapeutics	0.00%	-7.70%	-25.65%	-39.15%	+11.96%
LNTH Lantheus	0.00%	+0.10%	+0.06%	-7.62%	+78.02%
PBH Prestige Consumer Healthcare	0.00%	-4.22%	+2.72%	-5.20%	-23.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRX Amneal Pharmaceuticals	2.80	Moderate Buy	$21.25	1.28% Upside
AXSM Axsome Therapeutics	2.86	Moderate Buy	$274.68	90.08% Upside
LNTH Lantheus	2.21	Hold	$107.44	7.45% Upside
PBH Prestige Consumer Healthcare	2.40	Hold	$67.67	39.32% Upside

Current Analyst Ratings Breakdown

Latest PBH, AXSM, LNTH, and AMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/26/2026	AXSM Axsome Therapeutics	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$258.00 ➝ $238.00
10/22/2026	AMRX Amneal Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$22.00 ➝ $24.00
10/15/2026	AXSM Axsome Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold (C+) ➝ Hold (C)
10/14/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/13/2026	LNTH Lantheus	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform ➝ Neutral	$115.00 ➝ $109.00
10/8/2026	AMRX Amneal Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
10/8/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$297.00 ➝ $295.00
10/6/2026	AMRX Amneal Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/1/2026	AMRX Amneal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/30/2026	PBH Prestige Consumer Healthcare	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy

(Data available from 10/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRX Amneal Pharmaceuticals	$3.02B	2.22	$1.61 per share	13.05	($0.23) per share	-91.23
AXSM Axsome Therapeutics	$638.50M	11.85	N/A	N/A	$1.75 per share	82.58
LNTH Lantheus	$1.54B	4.24	$6.40 per share	15.63	$16.43 per share	6.09
PBH Prestige Consumer Healthcare	$1.09B	2.11	$5.29 per share	9.18	$39.89 per share	1.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRX Amneal Pharmaceuticals	$72.06M	$0.49	42.86	19.43	2.38	5.05%	-584.46%	7.78%	N/A
AXSM Axsome Therapeutics	-$183.17M	-$3.75	N/A	39.70	N/A	-24.68%	-265.55%	-28.10%	11/2/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.15	17.82	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
PBH Prestige Consumer Healthcare	$190.30M	$3.57	13.60	9.54	1.50	15.57%	11.39%	5.66%	11/5/2026 (Estimated)

Latest PBH, AXSM, LNTH, and AMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	LNTH Lantheus	$1.26	N/A	N/A	N/A	$360.82 million	N/A
11/5/2026	Q2 2027	PBH Prestige Consumer Healthcare	$1.07	N/A	N/A	N/A	$329.15 million	N/A
11/2/2026	Q3 2026	AXSM Axsome Therapeutics	-$0.6215	N/A	N/A	N/A	$250.22 million	N/A
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8921	-$0.99	-$0.0980	-$0.99	$221.11 million	$218.38 million
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/6/2026	Q1 2027	PBH Prestige Consumer Healthcare	$0.8940	$0.98	+$0.0860	$0.61	$253.02 million	$265.71 million
7/30/2026	Q2 2026	AMRX Amneal Pharmaceuticals	$0.24	$0.30	+$0.06	$0.18	N/A	$796.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRX Amneal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRX Amneal Pharmaceuticals	77.65	2.20	1.44
AXSM Axsome Therapeutics	1.52	1.43	1.34
LNTH Lantheus	0.43	3.06	2.89
PBH Prestige Consumer Healthcare	1.06	3.23	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRX Amneal Pharmaceuticals	31.82%
AXSM Axsome Therapeutics	81.49%
LNTH Lantheus	99.06%
PBH Prestige Consumer Healthcare	99.95%

Insider Ownership

Company	Insider Ownership
AMRX Amneal Pharmaceuticals	17.30%
AXSM Axsome Therapeutics	20.60%
LNTH Lantheus	1.70%
PBH Prestige Consumer Healthcare	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRX Amneal Pharmaceuticals	8,500	319.35 million	264.11 million	Optionable
AXSM Axsome Therapeutics	925	52.38 million	41.59 million	Optionable
LNTH Lantheus	1,193	65.30 million	64.19 million	Optionable
PBH Prestige Consumer Healthcare	890	47.38 million	46.66 million	Optionable

PBH, AXSM, LNTH, and AMRX Headlines

Recent News About These Companies

Prestige Consumer Healthcare Inc. $PBH Stake Lifted by Leeward Investments LLC MA

October 26 at 5:51 AM | marketbeat.com

Prestige Consumer Healthcare Inc (PBH) Shares Fall 3.4% -- What GF Score of 70 Tells Investors

October 23 at 9:00 PM | gurufocus.com

Contrasting Prestige Consumer Healthcare (NYSE:PBH) and RYTHM (NASDAQ:RYM)

October 19, 2026 | americanbankingnews.com

27,280 Shares of Prestige Consumer Healthcare Inc. $PBH Purchased by Milestone Asset Management LLC

October 16, 2026 | marketbeat.com

Prestige Consumer Healthcare (NYSE:PBH) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell?

October 16, 2026 | marketbeat.com

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?

October 15, 2026 | uk.finance.yahoo.com

Prestige Consumer Healthcare to Release Fiscal 2027 Second Quarter Earnings Results

October 14, 2026 | globenewswire.com

Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: A Potential 40% Upside Awaits Investors

October 12, 2026 | directorstalkinterviews.com

163,834 Shares in Prestige Consumer Healthcare Inc. $PBH Bought by Congress Asset Management Co.

October 8, 2026 | marketbeat.com

Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Upgraded by Zacks Research

October 2, 2026 | marketbeat.com

Best Value Stocks to Buy for October 1st

October 1, 2026 | zacks.com

PBH vs. NEOG: Which Stock Is the Better Value Option?

September 30, 2026 | zacks.com

More Than Half of U.S. Women Have Avoided Talking About an Intimate Wellness Concern Because They Felt Embarrassed or Uncomfortable, New Summer's Eve® Survey Finds

September 30, 2026 | prnewswire.com

Has Prestige Consumer Healthcare (PBH) Fallen Far Enough On Earnings?

September 29, 2026 | finance.yahoo.com

Prestige Consumer Healthcare (PBH) Could Be 30% Undervalued After Its 2027 Targets

September 29, 2026 | finance.yahoo.com

Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow

September 27, 2026 | marketbeat.com

Prestige Consumer Healthcare stock gains ahead of Sidoti event

September 22, 2026 | ad-hoc-news.deA

Prestige Consumer Healthcare stock falls as analysts stay cautious

September 20, 2026 | ad-hoc-news.deA

Prestige Consumer Healthcare stock falls after sharp drop toward 52-week low

September 19, 2026 | ad-hoc-news.deA

PBH or NEOG: Which Is the Better Value Stock Right Now?

September 14, 2026 | zacks.com

Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript

September 10, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH, AXSM, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

$21.03 +0.65 (+3.17%)

Closing price 03:59 PM Eastern

Extended Trading

$21.03 +0.00 (+0.02%)

As of 04:10 PM Eastern

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Axsome Therapeutics NASDAQ:AXSM

$143.99 -1.05 (-0.72%)

Closing price 03:59 PM Eastern

Extended Trading

$143.50 -0.49 (-0.34%)

As of 04:10 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Lantheus NASDAQ:LNTH

$99.93 +0.13 (+0.13%)

Closing price 03:59 PM Eastern

Extended Trading

$99.92 -0.01 (-0.01%)

As of 04:10 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Prestige Consumer Healthcare NYSE:PBH

$48.26 +0.46 (+0.96%)

Closing price 03:59 PM Eastern

Extended Trading

$48.16 -0.10 (-0.21%)

As of 04:10 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBH, AXSM, LNTH, and AMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBH, AXSM, LNTH, and AMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBH, AXSM, LNTH, and AMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH, AXSM, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Axsome Therapeutics NASDAQ:AXSM

Lantheus NASDAQ:LNTH

Prestige Consumer Healthcare NYSE:PBH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBH, AXSM, LNTH, and AMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBH, AXSM, LNTH, and AMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBH, AXSM, LNTH, and AMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH, AXSM, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Axsome Therapeutics NASDAQ:AXSM

Lantheus NASDAQ:LNTH

Prestige Consumer Healthcare NYSE:PBH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools